3sbio, Inc. · HKEX:1530
3sbio — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
43 slides from 3sbio's conference presentation, Jan 16, 2025
Slide 1: Corporate Presentation
Corporate Presentation 43rd Annual J.P. Morgan Healthcare Conference Tony He (hexiang@3sbio.com) Chief Financial Officer January 16th, 2025 San Francisco, California
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: 01. Overview
01. Overview 3
Slide 4: Over Three Decades of Excellence and Continuous Innovation
Over Three Decades of Excellence and Continuous Innovation RMB YSP ® Mandi® Inleusin® EPIAO® SEPO® TPIAO® (Pre-filled injection) （Minoxidil (IL-2) （rhEPO） （rhEPO） （rhTPO） Foam） Interfen® （interferon α-2ª） IV Sucrose® Qiming Keli® Xenopax® Byetta® Cipterbin® Remitch® BCG-PSN® Mandi® SPARIN® Yisaipu®
Slide 5: Where We Are Today
Where We Are Today 24.5% 28 >50 2013-2023 Revenue CAGR Disclosed R&D Pipelines Approved Products 42nd 7 China's Top 100 Pharma by Facilities Globally Overall Industry Capability ￥7.8 Bn ~700 ~3,000 Commercialization Revenue in 2023 R&D Staffs Professionals >4.5% AA MSCI ESG Rating ￥7.9 Bn >10% Divid
Slide 6: Consistent Track Record of Annual Growth for Over a Decade
Consistent Track Record of Annual Growth for Over a Decade TPO Mandi rhEPO YSP Others 7.8bn 6.9bn 10 yrs CAGR 24.5% 6.4bn 7% 5.6bn 5.3bn 9% 12% 4.6bn 12% 16% 14% 11% 3.8bn 18% 22% 13% 17% 2.8bn 24% 9% 14% 7% 27% 1.7bn 20% 54% 28% 1.1bn 23% 48% 49% 0.9bn 28% 49% 44% 43% 36% 54% 52% 27% 26% 35% 39% 36
Slide 7: Milestones in 2024
Milestones in 2024 • rhTPO showed various • TPIAO® was • TPIAO® NDA for • Inetetamab’s • Exclusive • Exclusive Oncology / • TPIAO® pediatric • rhTPO was • TeAiSheng® studies in APASL for its recommended by CLDT accepted several studies commerciali- commercialization ITP approved by recommended by la
Slide 8: Strong Financial Performance
Strong Financial Performance Revenue Gross Profit Attributable Profits Financial Resources 16.0 % YOY 18.6 % YOY 11.1% YOY 7.9 Bn Bn Bn Bn Gross margin 86.5% Bn 7.8 6.9 6.6 8.2 7.9 6.4 1.92 7.4 5.7 5.3 1.65 1.55 4.4 3.8 3.8 1.09 3.2 0.98 5.0 4.5 2021 2022 2023 2023H1 2024H1 2021 2022 2023 2023H1 202
Slide 9: Globally Recognized Commercialization Professionals
Globally Recognized Commercialization Professionals • Various 3SBio’s products have been approved overseas, including TPIAO, Yisaipu, EPIAO, SEPO, etc. Proven marketing team with over 30 years of recognition • The registration has covered nearly 40 countries and regions around the world, with the bu
Slide 10: Comprehensive Manufacturing Capabilities
Comprehensive Manufacturing Capabilities 7 plants worldwide with high manufacturing capacity supplying both development and commercialization 1500+ production professionals Established manufacturing and R&D facilities in Shenyang, Shanghai, Hangzhou, Shenzhen, Dongguan and Italy Shenzhen – Shenyang
Slide 11: End-to-End R&D Centers and Platforms
End-to-End R&D Centers and Platforms Four Centers, Five Platforms - R&D, Registration, Clinical trials, Manufacture Shenyang Shanghai Shenzhen Hangzhou BsAb & Multifunctional Fc Ab Maturity and Ab Selection Pre-clinical Animal Multispecific Ab Protein Optimization Drug Effect Platform Platform Platf
Slide 12: Various ESG Achievements
Various ESG Achievements • Take social responsibilities, devote to public welfare actively • Industry leading recognition, MSCI ESG rated AA for 3 consecutive years • Listed in the "TOP20 ESG Competitiveness of Chinese Listed Pharmaceutical Companies" list for 3 consecutive years • Wind ESG A rating
Slide 13: 02. Pipelines by Therapeutic Areas
02. Pipelines by Therapeutic Areas 13
Slide 14: Innovative Pipeline
Innovative Pipeline Therapeutic Areas Candidates Pre-clinical RMB IND Ph I Ph II Ph III NDA 2 Pre-clinical SSS06 Long-acting rhEPO NDA RD01 Long-acting rhEPO Nephrology TRK-820 Remitch CLD pruritus SSS17 HIF inhibitor TPO-106 CLDT NDA 6 IND& Phase I 304R anti-CD20 Ab CS1003 anti-PD1 Ab Licensed prod
Slide 15: TPIAO — the Only Commercialized rhTPO Globally
Hematology & Oncology: TPIAO — the Only Commercialized rhTPO Globally Revenue of TPIAO Top 1 market share RMB Mn 1 66% 1 market share in terms of sales TPIAO,66.2% 4,205 3,080 3,397 2,476 2,019 2021 2022 2023 2023H1 2024H1 TPIAO Class A（Interleukin-11） Class B（Oral TPO-RA） Chemotherapy Cancer therap
Slide 16: TPIAO — Improving Clinical Recognition
Hematology & Oncology: TPIAO — Improving Clinical Recognition Mar, 2024 Liver Diseases • Several studies of rhTPO showed in APASL, shared academic APASL1 achievements in acute liver failure, acute-on-chronic liver failure (ACLF), liver cancer ablation severe thrombocytopenia (sTCP) etc. “Standard fo
Slide 17: Cipterbin — More Choice for Patients
Hematology & Oncology: Cipterbin — More Choice for Patients Revenue of Cipterbin Top recommendation among H medications for HER2-positive advanced breast cancer Top recommendations: (1) THP1 (1A); (2) TXH2 (2A) RMB Mn Anti-HER2 mAb (H), including Trastuzumab, its biosimilars, and inetetamab YOY：48.9
Slide 18: Synergistic Candidates with TPIAO and Cipterbin
Hematology & Oncology: Synergistic Candidates with TPIAO and Cipterbin Hematology • Obtained commercialization rights in Mainland China Eltrombopag for Oral Suspension Clifutinib Besylate ITP • Compared with the first-generation drug, FLT3-ITD+ R/R AML Clifutinib exhibits stronger FLT3 inhibitory Ph
Slide 19: PD1/VEGF Summary of Phase 1 and Phase 2 Data From Ongoing Trials
Hematology & Oncology: PD1/VEGF Summary of Phase 1 and Phase 2 Data From Ongoing Trials Drug Name 707 Phase (Trial) Phase 1a/1b Phase 2 Phase 2 Phase 2 1L PD-L1+ NSCLC 1L NSCLC ≥ 3L mCRC 1L mCRC Indication Advanced Solid Tumors RASm or BRAFm, RASm or BRAFm, without EGFR/ALK alterations, ECOG 0-1, PD
Slide 20: Nephrology: Top Market Share rhEPO & Only Symptomatic Drug for Dialysis Pruritus
Nephrology: Top Market Share rhEPO & Only Symptomatic Drug for Dialysis Pruritus in China Revenue of rhEPO Remitch® Narfuraphine hydrochloride orally disintegrating tablets RMB Mn 1st and Exclusive commercialized domestic YOY：11.3% symptomatic drug of moderate-to-severe dialysis pruritus, avoid resp
Slide 21: Nephrology: More Pipelines & Indications
Nephrology: More Pipelines & Indications SSS06 Glycosylation sites • Extended half-life and longer dosing intervals, modified EPO matching treatment cycles of chemotherapies SSS06 NuPIAO（rESA） CKD anemia • NDA accepted for review CIA NDA accepted for review 10% Penetration rate • Rank No.2 among dom
Slide 22: Yisaipu — The Preferred Biopharmaceutical for Chronic Diseases Treatment
Autoimmune: Yisaipu — The Preferred Biopharmaceutical for Chronic Diseases Treatment Revenue of Yisaipu Improving market penetration RMB Mn • Enhance hospitals coverage and related department coverage, prompt market YOY：9.5% penetration Expand new formulation • Pre-filled syringe got approval and ma
Slide 23: Focus on Broad Chinese Autoimmune Market
Autoimmune: Focus on Broad Chinese Autoimmune Market LN: lupus nephritis 0.6 # of patients in millions IBD: inflammatory bowel disease LN 0.6 0.6 SLE: systemic lupus erythematosus IBD 0.5 0.7 PN: prurigo nodularis Dermatology 1.2 AS: ankylosing spondylitis Rheumatism 1.0 PsO: psoriasis SLE 1.0 1.0 C
Slide 24: Build the most Competitive Autoimmune Pipeline in China
Autoimmune: Build the most Competitive Autoimmune Pipeline in China Indication IND Ph I Ph II Ph III NDA Autoimmune pipeline strategy Moderate-to-severe 2024A PsO 608 Indications Product pipeline The new indications include AD, anti-IL-17A Ab coverage of development, CRSwNP, COPD, moderate to AS mar
Slide 25: Mandi — No.1 OTC Dermatology Brand in China
Consumer Health: Mandi — No.1 OTC Dermatology Brand in China Highly recognized scientific and effective hair growth choice Digital marketing covers the broadest population • Minoxidil, as a scientific, effective, safe and convenient hair growth • Deepen the cooperation with leading platforms product
Slide 26: Mandi — No.1 OTC Dermatology Brand in China
Consumer Health: Mandi — No.1 OTC Dermatology Brand in China 1st Generation 2nd Generation Everyday Mandi Tincture Mandi Foam Products • Mandi (60mL, 90mL) • Mandi for Female (30mL) • Approved with OTC in Jan 2024; • Mandi “Stand on” Shampoo, conditioner • Innovative technology, fill the gap for ski
Slide 27: New Acne Treatment Choice for Teenagers - Winlevi
Consumer Health: New Acne Treatment Choice for Teenagers - Winlevi® WS204 Clascoterone cream Acne vulgaris in 12 years and older 1st new mechanism of action in acne approved by the FDA in 40 years Phase III Finished enrollment • Approved by FDA in Clinical trial shows: November 20211 Winlevi® could
Slide 28: Vast Opportunities in Weight Management Market - Semaglutide
Consumer Health: Vast Opportunities in Weight Management Market - Semaglutide Number of people with obesity in China Forecast of Chinese weight Overweight/obesity rate among loss drug market size1 (Est. 2030): adult Chinese residents >50% 329 mn 1 2020 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E
Slide 29: 03. Business Development
03. Business Development 29
Slide 30: Business Development Strategies
Business Development Strategies Strategic Investment License-In License-Out • In start ups with FIC or BIC potential • Beef up product line in existing • To promote self-developed innovative products abroad to achieve long-term strategic therapeutic areas to scale up revenues and enter the global ma
Slide 31: Recent License-in Deals: Commercialization Rights of Late-stage Clinical Products
Recent License-in Deals: Commercialization Rights of Late-stage Clinical Products ➢ 24 Oct 2024 ➢ 25 Nov 2024 Obtained exclusive commercialization rights of Paclitaxel Oral Obtained exclusive commercialization rights of Clifutinib besylate Solution in Mainland China & HK in Mainland China ◆ The firs
Slide 32: Recent Investments: Innovative Early-Stage R&D Platform
Recent Investments: Innovative Early-Stage R&D Platform Strategically investing in FIC/BIC start-ups and empower R&D from long term perspective 15 Nov 2024 2024.11.16 Lead the A+++ Participate in financing round the A+ financing of NK CellTech round of C-RAY NK CellTech —— Focusing on the discovery
Slide 33: What to Expect in 2025?
What to Expect in 2025? Continuous Growth in Revenue and Profits NDAs IND Applications License In and Out Transactions 33
Slide 34: Technical Supplements
Technical Supplements 34
Slide 35: SSS06 (rESP) in Anemia of CRF
SSS06 (rESP) in Anemia of CRF(Chronic Renal Failure) The phase III trial demonstrated that rESP was safe and effective for anemia of CRF1 patients on stable hemodialysis as rhEPO rESP vs. rhEPO clinical efficacy data: 2nd- generation EPO rhEPO （dosage and schedule rESP QOW • Genetically modified rhE
Slide 36: 608 (anti-IL-17A mAb) in PsO
608 (anti-IL-17A mAb) in PsO Phase III study data in PsO unblinds: met primary endpoints and all secondary endpoints Primary endpoints Key secondary endpoints Secondary endpoints • The primary efficacy data at 12 weeks were excellent, maintenance with rapid response rate and obvious efficacy advanta
Slide 37: 611 (Anti-IL-4R mAb) in Atopic Dermatitis
611 (Anti-IL-4R mAb) in Atopic Dermatitis Phase II trial of 611 in AD shows better performance than control group • Data from Week shows 611 has better performance IGA declined ≥2 from baseline than Dupilumab on EASI-75 and NRS IGA 0/14 and 46.7% declined ≥2 from baseline 41.9% 33.3% 35.5% EASI 752
Slide 38: 611 (anti-IL-4R mAb) in CRSwNP
611 (anti-IL-4R mAb) in CRSwNP Phase II study in CRSwNP shows significant efficacy • The W16 data showed that the efficacy of all 611 Note: 611 shows W16 data, Dupilumab shows W24 data doses (Q2W and Q4W) was clear and significantly 2.5 2.11 Changes from baseline better than that of placebo 2 1.89 1
Slide 39: 613 (Anti-IL-1β mAb) in Acute Gouty Arthritis
613 (Anti-IL-1β mAb) in Acute Gouty Phase II study of 613 in acute gouty arthritis met primary endpoints Recurrence rate of acute gout in 12 weeks was significantly • Effect begins 6 Hrs after administration lower than control group 16/31 • 613 performed better in reducing pain with time Patients wi
Slide 40: 610 (Anti-IL-5 mAb) in Eosinophilic Asthma
610 (Anti-IL-5 mAb) in Eosinophilic Asthma Phase II data indicates 610 could significantly improve the pulmonary function of asthma patients, and shows a better trend than its similar products 610 VS its similar products: improvement in lung function (FEV1) in subjects with severe asthma • Progress
Slide 41: 626 2nd Generation BDCA2 mAb with BIC Potential
626 2nd Generation BDCA2 mAb with BIC Potential SSGJ-626 Huge Unmet Medical Needs Through inhibiting plasmacytoid dendritic cell Mechanism (pDC), the secretion of IFNα was inhibited. Thus regulating the activity of a range of immune cells Strong BDCA2 affinity (KD: 2.48E-11) Very high Degree of huma
Slide 42: 627 A Potential BIC Long-Lasting anti-TL1A Humanized mAb
627 A Potential BIC Long-Lasting anti-TL1A Humanized mAb TL1A: A Novel Target for IBD Treatment Program Highlights • TNF-like ligand 1A, a member of the tumor necrosis factor family • Best-in-class, preclinical stage, anti-TL1A mAb; • Potential Indication: Ulcerative Colitis, Crohn's disease • Biolo
Slide 43: SSS40 (Anti-NGF mAb) in Cancer Pain
SSS40 (Anti-NGF mAb) in Cancer Pain $10 billion cancer pain market globally The progress of SSS40 cancer pain indications ranked among millions of cancer pain patients in China the top three in China • SSS40 anti-NGF mab is currently undergoing phase Ib/II enrollment, and is expected to finish the e
3SBio — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix